Literature DB >> 12440623

Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.

Michael I Ebright1, Maureen F Zakowski, Jocelyne Martin, Ennapadam S Venkatraman, Vincent A Miller, Manjit S Bains, Robert J Downey, Robert J Korst, Mark G Kris, Valerie W Rusch.   

Abstract

BACKGROUND: The histologic criteria defining bronchioloalveolar carcinoma (BAC) were recently revised, but it is unclear whether these criteria predict clinical behavior. This study determined the outcome of resected BAC in relationship to clinical and radiologic disease pattern, and pathologic features.
METHODS: Between 1989 and 2000, 100 consecutive surgically treated patients with adenocarcinomas exhibiting various degrees of BAC features were retrospectively studied. Histology was reviewed; tumors were classified as pure BAC, BAC with focal invasion, and adenocarcinoma with BAC features. Clinical and radiologic pattern were classified as unifocal, multifocal, or pneumonic. Demographic data, tumor stage, and outcome were recorded. Survival was analyzed by the Kaplan-Meier method, and prognostic factors were determined by the log-rank test.
RESULTS: Patient median age was 65, and 74% of the patients were female. Pure BAC, BAC with focal invasion, and adenocarcinoma with BAC features occurred in 47, 21, and 32 patients, respectively. Unifocal disease occurred in 64 patients, multifocal in 29, and pneumonic in 7. Seventy-one patients had stage I/II tumors, 22 had stage III/IV, and 7 patients had Stage X tumors. Overall 5-year survival was 74%. There was no significant difference in survival among the three histologic subtypes. The pneumonic pattern had significantly worse survival compared with unifocal and multifocal patterns. Pathologic stage predicted survival, with 5-year survivals for I/II and III/IV of 83.7% and 59.6%, respectively.
CONCLUSIONS: Clinical pattern and pathologic stage, but not the degree of invasion on histologic examination predict survival. Multifocal disease is associated with excellent long-term survival after resection. The favorable survival of stage III/IV BAC indicates that the current staging system does not fully describe this disease in patients undergoing resection because of its distinct tumor behavior.

Entities:  

Mesh:

Year:  2002        PMID: 12440623     DOI: 10.1016/s0003-4975(02)03897-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  21 in total

1.  Reevaluation of survival and prognostic factors in pathologic stage I lung adenocarcinoma by the new 2009 TNM classification.

Authors:  Xiaohong Fan; Xueyan Zhang; Huimin Wang; Bo Jin
Journal:  Tumour Biol       Date:  2014-06

Review 2.  Reclassification of early stage pulmonary adenocarcinoma and its consequences.

Authors:  Annikka Weissferdt; Cesar A Moran
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

3.  [Progressive upper lobe consolidation in a 73-year old healthy woman].

Authors:  S Tasci; S Lentini; R Manka; N Friedrichs; B Lüderitz
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

4.  Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.

Authors:  Katerina Politi; Maureen F Zakowski; Pang-Dian Fan; Emily A Schonfeld; William Pao; Harold E Varmus
Journal:  Genes Dev       Date:  2006-05-16       Impact factor: 11.361

5.  Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).

Authors:  Daniel T Milton; Mark G Kris; Jorge E Gomez; Marc B Feinstein
Journal:  Support Care Cancer       Date:  2004-11-19       Impact factor: 3.603

Review 6.  Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.

Authors:  Jody C Chuang; Joseph B Shrager; Heather A Wakelee; Joel W Neal
Journal:  Clin Ther       Date:  2016-06-29       Impact factor: 3.393

7.  Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.

Authors:  Maureen F Zakowski; Sanaa Hussain; William Pao; Marc Ladanyi; Michelle S Ginsberg; Robert Heelan; Vincent A Miller; Valerie W Rusch; Mark G Kris
Journal:  Arch Pathol Lab Med       Date:  2009-03       Impact factor: 5.534

8.  Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features.

Authors:  Sarit Aviel-Ronen; Bradley P Coe; Suzanne K Lau; Gilda da Cunha Santos; Chang-Qi Zhu; Dan Strumpf; Igor Jurisica; Wan L Lam; Ming-Sound Tsao
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-15       Impact factor: 11.205

9.  Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma.

Authors:  Yi-Ran Cai; Hai-Qing Zhang; Zong-DE Zhang; Jing Mu; Zi-Hui Li
Journal:  Oncol Lett       Date:  2010-12-23       Impact factor: 2.967

10.  A case report on bronchoalveolar carcinoma presenting as non-resolving consolidation.

Authors:  Sheikh Shoib; Javid A Malik; Tasleem Arif; Haamid Bashir
Journal:  Med J Islam Repub Iran       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.